KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis.

Silvio Danese, Rupert W Leong, Bruce E Sands, Tony Ma, Colleen Marano, Laurent Peyrin-Biroulet

Aliment Pharmacol Ther 62(5) 483-492

PMID40668079
PMCIDPMC12343057
DOI10.1111/apt.70264
发表日期2025-07-16
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Achievement of disease clearance (simultaneous symptomatic remission and histo-endoscopic mucosal improvement [HEMI]) following induction therapy may lead to better long-term outcomes in ulcerative colitis (UC). AIM: To evaluate disease clearance in the phase 3 UNIFI program and its association with long-term outcomes. METHODS: UNIFI comprised randomised, placebo-controlled induction and maintenance studies and a long-term extension, which evaluated intravenous ustekinumab induction (130 mg or ~6 mg/kg) and subcutaneous ustekinumab maintenance therapy (90 mg every 8 or 12 weeks) through 4 years in patients with UC. RESULTS: Disease clearance was achieved by 5.9%, 15.2% and 15.1% of patients 8 weeks after placebo or ustekinumab 130 mg or ~6 mg/kg induction, respectively. Among ustekinumab induction responders randomised to ustekinumab maintenance therapy who did or did not achieve disease clearance 8 weeks after induction, 63.6% and 35.2% (nominal p < 0.001), respectively, achieved clinical remission (Mayo score ≤ 2, no individual subscore > 1) at Week 44. Among ustekinumab induction responders randomised to ustekinumab maintenance therapy who achieved disease clearance, symptomatic remission without HEMI, or neither symptomatic remission nor HEMI 8 weeks after induction, 73.4%, 53.5% (nominal p = 0.002) and 45.1% (nominal p < 0.001), respectively, achieved symptomatic remission (Mayo stool frequency subscore 0/1, rectal bleeding subscore 0) and 58.2%, 46.5% (nominal p = 0.09) and 42.7% (nominal p = 0.05), respectively, achieved Inflammatory Bowel Disease Questionnaire remission (score ≥ 170) at Week 200. CONCLUSIONS: Patients who achieved disease clearance 8 weeks after ustekinumab induction were more likely to be in long-term clinical, symptomatic and quality of life remission with ustekinumab maintenance treatment than patients who did not. TRIAL REGISTRATION: NCT02407236.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

FIGURE 5

FIGURE 5 Time‐to‐treatment failure event through maintenance Week 220 by induction efficacy categories. Events of interest were defined as UC‐related surgery or hospitalisation, AE of UC, or discontinuation of study agent due to an AE of worsening UC or lack of efficacy. All p ‐values are nominal. AE, adverse event; HEMI, histo‐endoscopic mucosal improvement; UC, ulcerative colitis.

Time-to-treatment_failure

Time-to-treatment failure

FIGURE 5 · Panel Time-to-treatment_failure

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel Time-to-treatment_failure 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Study design. *Patients who were receiving placebo SC at the time of study unblinding, which occurred after completion of the maintenance study analysis, were discontinued. IV, intravenous; PBO, placebo; q12w, every 12 weeks; q8w, every 8 weeks; SC, subcutaneous; UST, ustekinumab.
非 KM Figure
FIGURE 2FIGURE 2 Achievement of disease clearance 8 weeks after IV ustekinumab induction (A) or at maintenance Week 44 among evaluable IV ustekinumab induction responders randomised to maintenance treatment (B). All p ‐values are nominal and are versus placebo. IV, intravenous; q12w, every 12 weeks; q8w, every 8 weeks; SC, subcutaneous.
非 KM Figure
FIGURE 3FIGURE 3 Achievement of outcomes at maintenance Week 44 by achievement of disease clearance following induction. All p ‐values are nominal. HEMI, histo‐endoscopic mucosal improvement.
非 KM Figure
FIGURE 4FIGURE 4 Achievement of symptomatic remission (A) or corticosteroid‐free symptomatic remission (B) through maintenance Week 200 by induction efficacy category. All p ‐values are nominal and are versus disease clearance. HEMI, histo‐endoscopic mucosal improvement.
非 KM Figure
FIGURE 6FIGURE 6 Achievement of IBDQ remission (total score ≥ 170) through maintenance Week 200 by induction efficacy categories. All p ‐values are nominal and are versus disease clearance. HEMI, histo‐endoscopic mucosal improvement; IBDQ, Inflammatory Bowel Disease Questionnaire.
非 KM Figure